Business
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
WHIPPANY, N.J., December 01, 2025--Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol) and Omnipaque™ (iohexol). Additionally, Bayer announced the addition of Vis
About this update from Bayer Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/cb996b68d9264405d9d8637f148f241d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7V7e_4d3BE8UDRwOKfCVKw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cb996b68d9264405d9d8637f148f241d","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol)","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Follows recent FDA clearance to expand the use of compatible contrast agent presentations, adding single-dose vials in addition to Imaging Bulk Package presentations","length":165,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Radiology suites now have the ability to further manage contrast consumption and waste, while providing greater flexibility for those transitioning to bulk contrast use","length":168,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":476,"olType":false},{"type":"text","content":"WHIPPANY, N.J., December 01, 2025--(BUSINESS WIRE)--Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol) and Omnipaque™ (iohexol). Additionally, Bayer announced the addition of Visipaque™ (iodixanol) in single-dose vials as Centargo’s fifth compatible contrast agent. This expansion now offers customers in high-throughput imaging suites a wider range of compatible contrast agents and presentations from Centargo.","length":751,"tagName":"p"},{"type":"text","content":""We know our customers operating high-volume suites, who serve dozens of patients daily, require flexible and cost-effective solutions to meet their unique needs," said Jill Carbone, Vice President and Head of Radiology North America Product &am...